 TEL AVIV, Israel, Aug. 13, 2021 PRNewswire -- Chemomab Therapeutics Ltd. Nasdaq: CMMB, a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced financial and operating results for the second quarter ended June 30, 2021 and provided a business update. 